Please login to the form below

Not currently logged in
Email:
Password:

EGFR inhibitor

This page shows the latest EGFR inhibitor news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s flat sales focus investor attention on M&A

Pfizer’s flat sales focus investor attention on M&A

Among the highlights cited by Read on the call were oncology drugs talazoparib - a PARP inhibitor due for filing shortly for breast cancer - along with ALK/ROS1 inhibitor lorlatinib and EGFR ... inhibitor dacomitinib for lung cancer, which are due for

Latest news

  • AZ’s immuno-oncology combo fails another lung cancer trial AZ’s immuno-oncology combo fails another lung cancer trial

    There is no doubt, however, that the study raises another question mark over the role of CTLA4 inhibitor tremelimumab. ... There was better news for AZ in cancer last week, after the company picked up FDA approval for its EGFR inhibitor Tagrisso

  • AZ makes case for first-line Tagrisso therapy in lung cancer AZ makes case for first-line Tagrisso therapy in lung cancer

    AstraZeneca says that new data from its FLAURA trial of EGFR inhibitor Tagrisso makes a compelling argument that the drug should be use ahead of other dugs in the class in ... using Tagrisso (osimertinib) first-line in EGFR-mutated non-small cell lung

  • Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

    The EMA and FDA have started the clock ticking on their appraisals for dacomitinib, a pan-EGFR tyrosine kinase inhibitor, for the first-line treatment of patients with locally advanced or ... September. The study showed that dacomitinib improved median

  • Lilly drops Hanmi-partnered arthritis drug Lilly drops Hanmi-partnered arthritis drug

    Lilly drops Hanmi-partnered arthritis drug. Concludes that its BTK inhibitor is likely to be clinically ineffective. ... Boehringer handed back rights to EGFR inhibitor olmutinib (HM61713) after serious side effects were seen in phase III trials.

  • Clock starts ticking on AZ’s first-line lung cancer filing in US Clock starts ticking on AZ’s first-line lung cancer filing in US

    Third-generation EGFR inhibitor Tagrisso (osimertinib) is already approved as a follow-up to older drugs in the class, including AZ’s own Iressa (gefitinib) product and Roche's Tarceva (erlotinib), ... were updated to include the use of Tagrisso in the

More from news
Approximately 1 fully matching, plus 53 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    EGFR-TK) inhibitor, which has so far been approved in non-small cell lung cancer, albeit after a much-delayed, stop-start regulatory journey. ... If approved, the drug would complement AZ's other NSCLC drug, Iressa, which is approved in NSCLC patients

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics